key: cord-0726300-87kyw7dp
authors: Al Ghorani, Hussam; Götzinger, Felix; Böhm, Michael; Mahfoud, Felix
title: Arterial Hypertension – Clinical trials update 2021
date: 2021-09-16
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2021.09.007
sha: 87cf446045603173e1673c27e4314213a391d0a0
doc_id: 726300
cord_uid: 87kyw7dp

Aim This review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. Data synthesis The trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, and management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension. Conclusions Hypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension.

Perspective 115

The Improving the Detection of Hypertension trial suggested that 1 week of HBP monitoring 116 (measured twice in the morning and twice in the evening) may be the most reliable method for 117 diagnosing hypertension. The use of "out-of-office" methods can help to diagnose various 118 phenotypes of hypertension, such as white-coat and masked hypertension. hypertension.

[6] A reduction in systolic blood pressure (SBP) by 10-20% during nighttime is 124 considered physiological dipping. An absence of ("non-dipping"), or reverse ("rising") SBP-125 dipping is associated with higher CVD risk. were 306 CVDs (119 stroke, 99 coronary artery disease, 88 heart failure events). Nighttime 131 device and monitoring protocol. The results suggest that nighttime BP levels and a riser pattern 139 were independently associated with higher risk of CVD, in particular heart failure, highlighting 140 the importance of antihypertensive approaches targeting elevated nighttime BP. 141 142

Cardio-pulmonary exercise testing provides the opportunity to assess the behavior of BP under 144 reproducible, standardized physical exercise conditions. There is an association between 145 exaggerated exercise SBP and risk of CVD during follow-up. [ It is known that angiotensin-converting enzyme-2 (ACE2) expression can be increased by 183 angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers 184 (ARBs).

[18] Since ACE2 facilitates SARS-CoV-2 entry into cells, concern have been 185 expressed that treatment with these drugs could increase the risk of severe COVID-19 ( It can be assumed that the use of these drugs leads to a long-term benefit, also during COVID-217 19, mediated via their beneficial cardiovascular effects. 218 219

Elderly patients with hypertension often have other comorbidities and therefore frequently 221 receive polypharmacotherapy, which can lead to adverse events and increased morbidity.

[27] 222 Therefore, "deprescribing" has been proposed as a strategy of reduction and optimization of 223 pharmacotherapy in the elderly.

[27] 224

The unblinded, non-inferiority OPTIMISE-trial examined whether antihypertensive medication 225 reduction is feasible, safe, and not associated with loss of SBP control.

[28] A total of 569 226 patients ≥80 years with SBP <150 mmHg, taking at least two different antihypertensive agents 227 were randomized to a strategy of medication reduction (removal of one hypertension drug, 228 n=282) or usual care (no changes in medication, n=287).

[28] The primary endpoint was 229 maintaining SBP <150 mmHg at 12-week follow-up; 86% of the participants in the medication 230 reduction group had a SBP <150 mmHg vs. 88% in the usual care group, indicating no 231 difference between the groups (adjusted risk reduction: 0.98; 97.5% 1-sited CI 0.92 to ∞; 232 p=0.01 for non-inferiority). Expectedly, SBP and DBP significantly increased by 3.4 mmHg 233 (95% CI 1.0 to 5.8; p=0.005) and 2.2 mmHg (95% CI 0.9 to 3.6; p=0:001) in the medication 234 reduction group, respectively. Of the 7 prespecified secondary endpoints, 5 showed no 235 significant difference between the strategies. However, medication reduction was only 236 sustainable in 187 (66.3%) participants at 12 weeks. 237

This study suggested that antihypertensive medication reduction can be achieved without 239 substantial changes in BP control in certain elderly patients but was maintained in only 2 out 240 of 3 patients at 12 weeks. In elderly patients, a risk-benefit assessment of intensified BP control 241 should be critically and individually evaluated. (low, medium, and high) for 4 weeks and received all meals but were free to drink calorie-free 280 beverages (e.g., water). After each period, energy intake, weight, self-reported thirst, and 24-281 hour urine volume were assessed. On both diets, weight was slightly but significantly reduced 282 with low sodium intake in participants on DASH diet (p trend=0.049) and in participants on 283 control diet (p trend=0.001). Furthermore, higher sodium levels were associated with more 284 thirst (p trend 0.001 for both diets), whereas urine volume was higher in the control diet group 285 (p trend=0.007). Moreover, lower sodium intake decreased both office SBP and DBP regardless 286 of diet (-3.1/-1.5 vs. -6.4/-3.2 mmHg, all p-trends <0.001). Additionally, sodium reduction did 287 not increase energy requirements to maintain a stable weight, but decreased thirst (in both diets) 288 and urine volume (control diet only), respectively. mmHg; 95% CI -2.1 to 0.9), there was a significant reduction in the RDN group (-4.7 mmHg; 334 95% CI -6.4 to -2.9). The primary endpoint, which was a baseline-adjusted change in mean 24-335 h SBP after 3 months, was reached. The between-group change of mean SBP was -3.9 mmHg 336 (Bayesian 95% credible interval: -6.2 to -1.6). This study is one of three randomized, sham- Caption: There is an increasing risk of coronary heart disease with increasing exercise systolic 592 blood pressure at moderate exercise workload (100 watt for six minutes) independent of systolic 593 blood pressure value at rest. The association appears to be linear. 

Impact of exaggerated blood 410 pressure response in normotensiveindividuals on future hypertension and prognosis: 411 Systematic reviewaccording to PRISMA guideline

Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With 415

Coronary Disease Risk in Healthy Men

COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, 419 and treatment options

Coronavirus Disease 2019 in China

Association of hypertension and 425 antihypertensive treatment with COVID-19 mortality: a retrospective observational 426 study

Antihypertensive Drugs and COVID-19 Risk

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients 463 admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Effect of Discontinuing vs Continuing Angiotensin-Converting

Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and out of the

Hospital in Patients Admitted with COVID-19: A Randomized Clinical Trial

An expert 471 opinion from the european society of hypertension-european union geriatric medicine 472 society working group on the management of hypertension in very old

Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure

Control in Patients with Hypertension Aged 80 Years and Older: The OPTIMISE 478

Cardiovascular outcomes and achieved blood pressure in patients with and without 487 diabetes at high cardiovascular risk

Achieved 490 blood pressure and cardiovascular outcomes in high-risk patients: results from 491 ONTARGET and TRANSCEND trials

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on 495 long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: Data 496 from the RE-LY trial

Results 500 from the DASH (Dietary Approaches to Stop Hypertension)-Sodium Trial

Dietary 503 Approaches to Stop Hypertension Dietary Intervention Improves Blood Pressure

Empagliflozin 514 reduces blood pressure in patients with type 2 diabetes and hypertension

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in 521 patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical 522 trial

Effect of dapagliflozin according to baseline systolic blood pressure in the

Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Efficacy of catheter-based renal denervation in the absence of antihypertensive 529 medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-530 controlled trial

Effect 533 of renal denervation on blood pressure in the presence of antihypertensive drugs

Rationale and design of two randomized sham-controlled trials of catheter-based renal 539 denervation in subjects with uncontrolled hypertension in the absence

OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of 541 antihypertensive medicat

Endovascular ultrasound renal denervation to treat hypertension ( RADIANCE-HTN

SOLO ): a multicentre , international , single-blind , randomised , sham-controlled trial

Six-Month

Results of Treatment-Blinded Medication Titration for Hypertension Control After 549

Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in 550 the RADIANCE-HTN SOLO Trial

Proceedings 553 from the 3rd European Clinical Consensus Conference for clinical trials in device-554 based hypertension therapies

Denervation Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess 563 Impact of Renal Denervation The DENERHTN Study

Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc 568 Analysis of the RADIANCE-HTN SOLO Study

Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation

Device-based therapies for 574 arterial hypertension

Figure 6: Blood pressure and complications in patients on therapeutic anticoagulation

Caption: Figures 6 A and 6 C show the Kaplan-Meier event curves according to mean-achieved 613 systolic blood pressure for all-cause death and stroke, respectively. Figure 6 B and 6 D 614 illustrated a j-shape associations between the mean-achieved systolic blood pressure and all-615 cause death and stroke

Figure 7: change in 24-hour systolic blood pressure after renal denervation 618 Caption: three randomized, sham-controlled trials demonstrating that radiofrequency-619

HTN)[43] renal denervation can significantly reduce systolic blood pressure

SBP: systolic blood pressure, 24-h SBP: 24-hour systolic blood